Evidence map›Paper›PMID 38633577›Full record

ArticleEClinicalMedicine2024

FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study.

Kastriot Kastrati, Thomas S Nakuz, Oana C Kulterer, Irina Geßl, Elisabeth Simader, Daniel Mrak, Michael Bonelli, Hans Peter Kiener, Florian Prayer, Helmut Prosch and 7 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Diagnostic Performance of [Diagnostics (Basel, Switzerland) · 2026
    Article
  3. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
  5. Article
  6. Molecular imaging of fibroblast activation in systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. [Frontiers in medicine · 2026
    Article
  11. Review
  12. EJNMMI research · 2025
    Article
  13. EJNMMI research · 2025
    Article
  14. [European journal of nuclear medicine and molecular imaging · 2025
    Observational
  15. Article
  16. Pilot study ofRespiratory research · 2025
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kastriot KastratiDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Thomas S NakuzDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Oana C KultererDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Irina GeßlDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Elisabeth SimaderDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Daniel MrakDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Michael BonelliDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Hans Peter KienerDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Florian PrayerDivision of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Helmut ProschDivision of General and Paediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Daniel AletahaDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Werner LangstegerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Tatjana Traub-WeidingerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Stephan BlümlDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Helga Lechner-RadnerDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Peter MandlDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) and a substantial contributor to hospitalisation, increased morbidity, and mortality. In-vivo evidence of ongoing tissue remodelling in IIM-ILD is scarce. We aimed to evaluate fibroblast activation in lungs of IIM-patients and control individuals using ⁶⁸Ga-labelled inhibitor of Fibroblast-Activation-Protein (FAPi) based positronic emission tomography and computed tomography imaging (PET/CT). Methods: In this prospective observational pilot study, consecutive patients with IIM and participants without rheumatic conditions or ILD serving as a control group were recruited at the Medical University of Vienna, Austria, and underwent FAPi PET/CT imaging. Standard-of-care procedures including clinical examination, assessment of severity of dyspnoea, high-resolution computed tomography (HR-CT), and pulmonary function testing (PFT) were performed on all patients with IIM at baseline and for patients with IIM-ILD at follow-up of 12 months. Baseline pulmonary FAPi-uptake was assessed by the maximum (SUVmax) and mean (SUVmean) standardized uptake values (SUV) over the whole lung (wl). SUV was corrected for blood pool background activity and target-to-background ratios (TBR) were calculated. We compared pulmonary FAPi-uptake between patients with IIM-ILD and those without ILD, as well as controls, and correlated baseline FAP-uptake with standard diagnostic tools such as HR-CT and PFT. For predictive implications, we investigated whether patients with IIM and progressive ILD exhibited higher baseline FAPi-uptake compared to those with stable ILD. Metrics are reported as mean with standard deviation (±SD). Findings: Between November 16, 2021 and October 10, 2022, a total of 32 patients were enrolled in the study. Three participants from the control group were excluded due to cardiopulmonary disease. In individuals with IIM-ILD (n = 14), wlTBR Interpretation: Our study demonstrates higher fibroblast activation in patients with IIM-ILD compared to non-ILD patients and controls. Intensity of pulmonary FAPi accumulation was associated with progression of ILD. Considering that this study was carried out on a small population, FAPi PET/CT may serve as a useful non-invasive tool for risk stratification of lung disease in IIM. Funding: The Austrian Research Fund.

Indexed as

Fibroblast activationFibrosisIdiopathic inflammatory myopathyInterstitial lung disease

Identifiers

PMID38633577
PMCPMC11019096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.